PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24321617-8 2014 Furthermore, abnormal expression of FosB, the immediate early gene of L-dopa induced dyskinesia (LID), was mitigated in the striatum by the combination treatment. Levodopa 70-76 FBJ osteosarcoma oncogene B Mus musculus 36-40 23769604-9 2014 Chronic L-DOPA treatment, which induced dyskinesia and aberrant FosB expression, restored spine density in D2R-MSNs but not in D1R-MSNs. Levodopa 8-14 FBJ osteosarcoma oncogene B Mus musculus 64-68 24650244-0 2014 Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson"s disease mouse model. Levodopa 33-39 FBJ osteosarcoma oncogene B Mus musculus 74-78 21310234-11 2011 In all groups, the L-DOPA-induced AIM scores correlated closely with the number of cells immunoreactive for tyrosine hydroxylase or FosB/ FosB in the striatum. Levodopa 19-25 FBJ osteosarcoma oncogene B Mus musculus 132-136 21310234-11 2011 In all groups, the L-DOPA-induced AIM scores correlated closely with the number of cells immunoreactive for tyrosine hydroxylase or FosB/ FosB in the striatum. Levodopa 19-25 FBJ osteosarcoma oncogene B Mus musculus 138-142 16139809-9 2006 Following acute L-DOPA treatment, FosB expression occurs in direct striatal output neurons, whereas chronic L-DOPA also induces FosB expression in nitric oxide synthase-positive striatal interneurons. Levodopa 108-114 FBJ osteosarcoma oncogene B Mus musculus 128-132 31306812-0 2019 Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Levodopa 56-62 FBJ osteosarcoma oncogene B Mus musculus 127-131 27312773-11 2016 By contrast, mice sustaining the lesion at 23months of age showed a striking susceptibility to the dyskinetic effects of both l-DOPA and apomorphine, which was associated with a pronounced drug-induced upregulation of FosB in the ventrolateral striatum. Levodopa 126-132 FBJ osteosarcoma oncogene B Mus musculus 219-223 27574484-9 2016 LID-induced hyper-phosphorylation of ERK1/2 and overexpression of FosB/DeltaFosB was markedly decreased in 6-OHDA-lesioned striatum of PA-5HT-treated mice, indicating that PA-5HT decreased the dopamine D1 receptor-hyperactivation induced by chronic treatment of L-DOPA in dopamine-denervated striatum. Levodopa 262-268 FBJ osteosarcoma oncogene B Mus musculus 66-70 25281315-6 2015 Moreover, 7-NI significantly reduced FosB and pAcH3 expression in the acutely and chronically l-DOPA-treated mice. Levodopa 94-100 FBJ osteosarcoma oncogene B Mus musculus 37-41 25164669-8 2014 Consistently, FosB/DeltaFosB expression, which was induced by long-term L-DOPA treatment in the lesioned striatum, was also decreased in AC5-KO mice. Levodopa 72-78 FBJ osteosarcoma oncogene B Mus musculus 14-18 18279311-10 2008 Finally, striatal TH-ir neurones are functionally active, expressing the neuronal activation marker FosB in response to L-DOPA treatment. Levodopa 120-126 FBJ osteosarcoma oncogene B Mus musculus 100-104 16139809-0 2006 ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Levodopa 60-66 FBJ osteosarcoma oncogene B Mus musculus 24-28 16139809-9 2006 Following acute L-DOPA treatment, FosB expression occurs in direct striatal output neurons, whereas chronic L-DOPA also induces FosB expression in nitric oxide synthase-positive striatal interneurons. Levodopa 16-22 FBJ osteosarcoma oncogene B Mus musculus 34-38 25193242-8 2016 In line with this observation, the accumulation of FosB produced by chronic L-DOPA was reduced in MSK1 knockout. Levodopa 77-83 FBJ osteosarcoma oncogene B Mus musculus 52-56 24857398-1 2015 BACKGROUND: Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway as well as FosB and dynorphin-B expression mediated by dopamine D1 receptor stimulation in the development of 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesia. Levodopa 215-244 FBJ osteosarcoma oncogene B Mus musculus 116-120 24857398-12 2015 CONCLUSIONS: The protein DREAM decreases development of L-DOPA-induced dyskinesia in mice and reduces L-DOPA-induced expression of FosB, phosphoacetylated histone H3, and dynorphin-B in the striatum. Levodopa 56-62 FBJ osteosarcoma oncogene B Mus musculus 131-135 24857398-12 2015 CONCLUSIONS: The protein DREAM decreases development of L-DOPA-induced dyskinesia in mice and reduces L-DOPA-induced expression of FosB, phosphoacetylated histone H3, and dynorphin-B in the striatum. Levodopa 102-108 FBJ osteosarcoma oncogene B Mus musculus 131-135 25233866-5 2014 The absence of MSK1 had no effect on the lesion or l-DOPA-induced ERK activation, but reduced l-DOPA-induced phosphorylation of histone H3 and FosB accumulation in the dopamine-denervated striatum. Levodopa 94-100 FBJ osteosarcoma oncogene B Mus musculus 143-147 25233866-8 2014 In conclusion, l-DOPA-induced activation of MSK1 contributes to histone H3 phosphorylation, induction of FosB, and Galphaolf up-regulation but appears not to be necessary for the development of LID. Levodopa 15-21 FBJ osteosarcoma oncogene B Mus musculus 105-109